The MRC/ABPI COPD Cohort v1.7 (COPDMAP)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01620645 |
Recruitment Status : Unknown
Verified June 2012 by University College, London.
Recruitment status was: Recruiting
First Posted : June 15, 2012
Last Update Posted : June 15, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
COPD | Radiation: CT scan and PA chest X-ray |

Study Type : | Observational |
Estimated Enrollment : | 400 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | The Mechanisms of Inflammation and Immunity in COPD and Their Relationship to Exacerbations and Disease Progression. |
Study Start Date : | February 2011 |
Group/Cohort | Intervention/treatment |
---|---|
COPD, GOLD II severity or above |
Radiation: CT scan and PA chest X-ray
All participants will receive a single high resolution CT scan of the chest. This will be performed using a low tube current, helical technique. Participants may also receive a plain chest X-ray if clinically indicated. The total research protocol dose is 2 mSv. The dose from the chest X-ray is insignificant compared with the dose from the CT scan of the chest, therefore all this dose can be considered to be additional to standard of care. A dose of 2 mSv represents a risk of radiation induced detriment of approximately 1 in 10,000 and is equivalent to about 11 months of average natural background radiation in the UK. |
Blood, sputum and urine samples will be collected. Commercially available ELISA assays will be be used to qualify inflammatory markers.
Quantitative bacterial culture will be performed on sputum samples. Bacterial and viral load will be determined by polymerase chain reaction (PCR). Proteomics such as Cholesterol, BNP, CRP by routine hospital assay techniques. Specific DNA sections will be selected from the genome to identify/confirm genes believed to be associated with different COPD phenotypes by molecular techniques.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 40 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Patients will be recruited from existing cohorts and may have participated in previously approved studies.
Potential primary care patients will be identified from databases held in practices and contacted, by the GP, by letter in the first instance. If the patient replies to the GP that they are willing to participate in the research, then a telephone call will be made by the research team to arrange a clinic visit.
Potential outpatient participants will be identified by the outpatient respiratory physician and if willing to participate will be referred to the research team via telephone call or referral letter.
Inclusion Criteria:
- Confirmed spirometric evidence of moderate to very severe COPD (stage II to IV) according to the WHO GOLD criteria:
- All patients FEV1/FVC <70%
- Stage II FEV1 50-80% predicted
- Stage III FEV1 30-50% predicted
- Stage IV FEV1 <30% predicetd or <50% predicted and chronic respiratory symptoms
- Past or present smokers
- Gender: male or female
- Age >40 years at recruitment
- Reasonable command of English to complete daily diary cards
Exclusion Criteria:
- History of asthma
- History of neoplasia
- History of other significant respiratory disease
- Pregnancy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01620645
United Kingdom | |
Royal Free Hampstead NHS Trust | Recruiting |
London, United Kingdom, NW3 2QG | |
Contact: Richa Singh, MA MBBS MRCP +442077940500 ext 34308 r.singh@ucl.ac.uk | |
Contact: Gavin Donaldson, BSc PhD +442077940500 ext 34308 g.donaldson@ucl.ac.uk | |
Principal Investigator: Wisia Wedzicha, BSc MBBS MD |
Responsible Party: | University College, London |
ClinicalTrials.gov Identifier: | NCT01620645 |
Other Study ID Numbers: |
CSP-83727 |
First Posted: | June 15, 2012 Key Record Dates |
Last Update Posted: | June 15, 2012 |
Last Verified: | June 2012 |